Computer-assisted evaluation of tumor response reduced errors and time of evaluation compared with standard-of-care.
Cryoablation was associated with good short-term oncologic control and an excellent safety profile in "healthier" patients.
The understanding of genetic conditions with predisposition to renal cell cancer is critical for developing better therapies.
Osimertinib confers a high overall response rate and encouraging progression-free survival among patients with non-small cell lung cancer (NSCLC).
Hormonal maintenance therapy after primary treatment significantly prolonged progression-free survival compared with observation,
Adjusting treatment dose after 2 courses of first-line therapy based on a positive PET scan does not improve progression-free survival.
First-line immune checkpoint inhibition is more cost-effective than chemotherapy for treatment-naïve, BRAF wild-type, stage IV melanoma.
Olaparib significantly prolonged progression-free survival compared with chemotherapy among patients with HER2-negative breast cancer.
Nivolumab was clinically active and well-tolerated among patients with treatment-refractory metastatic squamous cell carcinoma of the anal canal (SCCA).
Reducing the cyclophosphamide dose for a subset of patients with rhabdomyosarcoma may increase the risk of disease recurrence.
Active surveillance appears to be a safe alternative to primary intervention for selected patients with small renal masses.
Atezolizumab (Tecentriq) combined with bevacizumab (Avastin) demonstrated antitumor activity compared with sunitinib as first-line therapy.
Patients with metastatic renal carcinoma (mRCC) treated with post-frontline agents had increased genomic alterations.
Bleomycin, etoposide, and cisplatin (BEP) for 1 cycle after orchiectomy is associated with a similar 2-year recurrence rate as BEP.
Studies presented in the last year demonstrated a revolutionary role for immune checkpoint inhibitors.
Pembrolizumab following platinum-based chemotherapy was associated with significantly longer overall survival, fewer adverse events.
David J. McConkey, MD, PhD, described how genomics can affect the clinical management of patients with bladder cancer.
The clinical outcomes when using neoadjuvant chemotherapy for muscle-invasive bladder cancer vary by molecular subtype.
Adding chemotherapy with fluorouracil and mitomycin to radiotherapy improves locoregional control.
Full-length androgen receptor (AR-FL) copy number derived from circulating tumor cells detected using a liquid biopsy.
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immunotherapy and the Future of Prostate Cancer Treatment
- Explaining Androgen Receptor-indifferent Prostate Cancer
- Dual Immunotherapy Active vs Sunitinib for PD-L1+ Advanced RCC
- 2017 ASCO GU Symposium: Updates in Managing Small Renal Masses
- First-line Immune Checkpoint Inhibition Cost-effective in Melanoma